Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Up 1,012.9% in January

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 2,090,000 shares, a growth of 1,012.9% from the December 31st total of 187,800 shares. Based on an average daily trading volume, of 6,360,000 shares, the short-interest ratio is presently 0.3 days. Currently, 3.7% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on APTO shares. StockNews.com began coverage on shares of Aptose Biosciences in a research report on Friday. They set a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a research report on Friday, January 10th.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp boosted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities & Exchange Commission. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Trading Down 8.1 %

APTO traded down $0.02 on Tuesday, hitting $0.19. 511,550 shares of the company were exchanged, compared to its average volume of 782,672. The firm has a 50-day moving average price of $0.22 and a two-hundred day moving average price of $0.36. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.20. The company has a market cap of $11.25 million, a price-to-earnings ratio of -0.06 and a beta of 0.87.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.